Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs

New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours

In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease 

Additional analysis from the NIAGARA study were presented

Findings are from an exploratory subgroup analysis of the KEYNOTE-826 

In the KEYNOTE-671, improvements in event-free survival and overall survival were observed after four years of follow up

Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer

The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study

Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones